Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2022-04-22 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for the notification of transactions by persons discharging managerial responsibilities (PDMRs). It identifies the individual (Michael J. Owen, a board member), the issuer (Zealand Pharma A/S), and the specific details of the transaction involving Restricted Share Units. This is a classic insider dealing/director's dealing disclosure.
2022-04-22 English
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies a specific board member (Alain Munoz) and details their transaction involving Restricted Share Units. This is a classic 'Director's Dealing' filing.
2022-04-22 English
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for the notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs). It identifies the individual (Kirsten Drejer, Vice Chairman), the issuer (Zealand Pharma A/S), and the specific details of the transaction (allocation of Restricted Share Units). This is a classic 'Director's Dealing' notification.
2022-04-22 English
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for the notification of transactions by persons discharging managerial responsibilities (PDMRs). It explicitly identifies the individual (Martin Nicklasson, Chairman of the board), the issuer (Zealand Pharma A/S), and details the allocation of Restricted Share Units. This is a classic insider dealing/director's transaction report.
2022-04-22 English
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Director's Dealing Classification · 100% confidence The document is an announcement regarding transactions in company securities by persons discharging managerial responsibilities (PDMRs). It explicitly states that the company has received information on these transactions and provides links to the specific notification files as attachments. This fits the definition of a Director's Dealing (DIRS) report, as it concerns insider transactions by management.
2022-04-22 Danish
Correction: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022
Major Shareholding Notification Classification · 100% confidence The document is a 'Standard form for notification of major holdings' submitted by Polar Capital LLP regarding their stake in Zealand Pharma A/S. It explicitly details the crossing of a 5% voting rights threshold, lists the chain of controlled undertakings, and follows the regulatory format for major shareholding disclosures as required by the Capital Markets Act. This fits the definition of a Major Shareholding Notification.
2022-04-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.